Modified mRNA Approach Extends CAR-T Cell Lifespan in Cancer Therapy
Scientists have developed a novel approach using modified TERT mRNA to significantly enhance the persistence and antitumor effectiveness of CAR-T cells. The breakthrough could address one of the major limitations in current cancer immunotherapy. This advancement shows particular promise for extending CAR-T applications beyond blood cancers to solid tumors.
In what could represent a significant step forward for cancer immunotherapy, researchers have reportedly developed a method to enhance CAR-T cell persistence and effectiveness using modified mRNA technology. According to recent study findings, the transient delivery of modified mRNA encoding telomerase reverse transcriptase (TERT) substantially improves both the longevity and tumor-fighting capabilities of these engineered immune cells.